These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1222 related items for PubMed ID: 17631211

  • 1. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial.
    Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, Landaas S, Rouleau JL, Domanski MJ, Hall C, Pfeffer MA, Braunwald E, PEACE Investigators.
    J Am Coll Cardiol; 2007 Jul 17; 50(3):205-14. PubMed ID: 17631211
    [Abstract] [Full Text] [Related]

  • 2. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease.
    Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R.
    N Engl J Med; 2005 Feb 17; 352(7):666-75. PubMed ID: 15716560
    [Abstract] [Full Text] [Related]

  • 3. Usefulness of combined high-sensitive C-reactive protein and N-terminal-probrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease.
    Huang PH, Lu TM, Wu TC, Lin FY, Chen YH, Chen JW, Lin SJ.
    Coron Artery Dis; 2008 May 17; 19(3):187-93. PubMed ID: 18418236
    [Abstract] [Full Text] [Related]

  • 4. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.
    Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, Rupprecht HJ, Bickel C, Tiret L, Cambien F, Gerstein H, Münzel T, Yusuf S, HOPE Study Investigators.
    Circulation; 2006 Jul 18; 114(3):201-8. PubMed ID: 16831981
    [Abstract] [Full Text] [Related]

  • 5. Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy.
    Tang WH, Steinhubl SR, Van Lente F, Brennan D, McErlean E, Maroo A, Francis GS, Topol EJ.
    Am Heart J; 2007 Jan 18; 153(1):36-41. PubMed ID: 17174634
    [Abstract] [Full Text] [Related]

  • 6. B-type natriuretic peptides: prognostic markers in stable coronary artery disease.
    Omland T.
    Expert Rev Mol Diagn; 2008 Mar 18; 8(2):217-25. PubMed ID: 18366308
    [Abstract] [Full Text] [Related]

  • 7. Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.
    Goei D, Hoeks SE, Boersma E, Winkel TA, Dunkelgrun M, Flu WJ, Schouten O, Bax JJ, Poldermans D.
    Coron Artery Dis; 2009 May 18; 20(3):219-24. PubMed ID: 19322079
    [Abstract] [Full Text] [Related]

  • 8. Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease.
    Rothenbacher D, Koenig W, Brenner H.
    Arch Intern Med; 2009 May 18; 166(22):2455-60. PubMed ID: 17159010
    [Abstract] [Full Text] [Related]

  • 9. Risk stratification in stable coronary artery disease: superiority of N-terminal pro B-type natriuretic peptide over high-sensitivity C-reactive protein, gamma-glutamyl transferase, and traditional risk factors.
    Bode E, Wuppinger T, Bode T, Alber H, Ulmer H, Pachinger O, Mair J.
    Coron Artery Dis; 2012 Mar 18; 23(2):91-7. PubMed ID: 22157356
    [Abstract] [Full Text] [Related]

  • 10. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.
    Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K, Ostergren J, Lonn E.
    Am J Cardiol; 2008 Sep 15; 102(6):733-7. PubMed ID: 18773998
    [Abstract] [Full Text] [Related]

  • 11. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
    Neuhold S, Huelsmann M, Strunk G, Stoiser B, Struck J, Morgenthaler NG, Bergmann A, Moertl D, Berger R, Pacher R.
    J Am Coll Cardiol; 2008 Jul 22; 52(4):266-72. PubMed ID: 18634981
    [Abstract] [Full Text] [Related]

  • 12. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
    Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E, PEACE Investigators.
    Circulation; 2007 Mar 27; 115(12):1528-36. PubMed ID: 17372173
    [Abstract] [Full Text] [Related]

  • 13. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study.
    Voors AA, von Haehling S, Anker SD, Hillege HL, Struck J, Hartmann O, Bergmann A, Squire I, van Veldhuisen DJ, Dickstein K, OPTIMAAL Investigators.
    Eur Heart J; 2009 May 27; 30(10):1187-94. PubMed ID: 19346228
    [Abstract] [Full Text] [Related]

  • 14. Predictive role of BNP and NT-proBNP in hemodialysis patients.
    Sun L, Sun Y, Zhao X, Xu C, Chen D, Li L, Ma Y, Rong S, Mei C.
    Nephron Clin Pract; 2008 May 27; 110(3):c178-84. PubMed ID: 18957868
    [Abstract] [Full Text] [Related]

  • 15. [Prognostic value of N-terminal pro-BNP-type natriuretic peptide in patients with stable coronary heart disease--secondary publication].
    Kragelund CB, Grønning BA, Køber L, Hildebrandt PR, Steffensen R.
    Ugeskr Laeger; 2006 Feb 13; 168(7):697-700. PubMed ID: 16494811
    [Abstract] [Full Text] [Related]

  • 16. Can measurement of B-type natriuretic peptide levels improve cardiovascular disease prevention?
    Campbell DJ.
    Clin Exp Pharmacol Physiol; 2008 Apr 13; 35(4):442-6. PubMed ID: 18307738
    [Abstract] [Full Text] [Related]

  • 17. Identification of potential outcome benefit from ACE inhibition after acute coronary syndrome: a biomarker approach using N-terminal proBNP.
    Squire I, Quinn P, Narayan H, Khan S, Dhillon O, Ng K, Kelly D, Davies J, Ng L.
    Heart; 2010 Jun 13; 96(11):831-7. PubMed ID: 20478862
    [Abstract] [Full Text] [Related]

  • 18. The interrelationship between preoperative anemia and N-terminal pro-B-type natriuretic peptide: the effect on predicting postoperative cardiac outcome in vascular surgery patients.
    Goei D, Flu WJ, Hoeks SE, Galal W, Dunkelgrun M, Boersma E, Kuijper R, van Kuijk JP, Winkel TA, Schouten O, Bax JJ, Poldermans D.
    Anesth Analg; 2009 Nov 13; 109(5):1403-8. PubMed ID: 19843778
    [Abstract] [Full Text] [Related]

  • 19. Pro-B-type natriuretic peptide levels in acute decompensated heart failure.
    Waldo SW, Beede J, Isakson S, Villard-Saussine S, Fareh J, Clopton P, Fitzgerald RL, Maisel AS.
    J Am Coll Cardiol; 2008 May 13; 51(19):1874-82. PubMed ID: 18466803
    [Abstract] [Full Text] [Related]

  • 20. Does admission NT-proBNP increase the prognostic accuracy of GRACE risk score in the prediction of short-term mortality after acute coronary syndromes?
    Timóteo AT, Toste A, Ramos R, Miranda F, Ferreira ML, Oliveira JA, Ferreira RC.
    Acute Card Care; 2009 May 13; 11(4):236-42. PubMed ID: 19742352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 62.